Replimune/$REPL

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Replimune

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Ticker

$REPL
Primary listing

Industry

Biotechnology

Employees

479

ISIN

US76029N1063

Replimune Metrics

BasicAdvanced
$732M
-
-$3.07
0.68
-

What the Analysts think about Replimune

Analyst ratings (Buy, Hold, Sell) for Replimune stock.

Bulls say / Bears say

Replimune's lead product candidate, RP1, in combination with nivolumab, has received FDA acceptance for a Biologics License Application with priority review for advanced melanoma, indicating potential for accelerated market entry. (Replimune Press Release)
The company maintains a strong cash position of $420.7 million as of March 31, 2024, expected to fund operations into the second half of 2026, providing financial stability for ongoing and future projects. (Replimune Press Release)
Replimune is expanding its pipeline with RP2, targeting advanced uveal melanoma, with a registration-directed clinical trial protocol near finalization following FDA input, potentially broadening its market reach. (Replimune Press Release)
Replimune reported a net loss of $215.8 million for the fiscal year ended March 31, 2024, an increase from the previous year's net loss of $174.3 million, indicating rising operational expenses. (Replimune Press Release)
Research and development expenses increased to $175.0 million for the fiscal year ended March 31, 2024, up from $126.5 million the previous year, reflecting higher costs associated with clinical and manufacturing activities. (Replimune Press Release)
The company's debt balance rose to $44.8 million as of March 31, 2024, compared to $28.6 million the previous year, indicating increased financial leverage. (Replimune Press Release)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.

Replimune Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Replimune Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $REPL

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs